There may be relief for women who suffer through hot flashes ... Drug Administration approved Veozah (generic name: fezolinetant), which is a one-of-a-kind treatment for menopause symptoms.

Veozah (fezolinetant) was approved in 2023 by the FDA to treat moderate to severe hot flashes. A similar drug, elinzanetant, ...

The FDA just approved Veozah to treat hot flashes in women. The medication is non-hormonal. Doctors say it’s a good option for menopausal women who don’t want to use hormones or can’t use ...

Veozah was approved in 2023. At the time, it was the first non-hormonal prescription option for treating hot flashes. The medication works by blocking neurokinin B, a receptor involved in the ...

The Food and Drug Administration (FDA) has approved a new medication to treat hot flashes in menopausal women. Veozah (fezolinetant) is designed to reduce the risk of developing moderate to severe hot ...

WASHINGTON -- Women have suffered for centuries with hot flashes ... who take Veozah will need to get routine bloodwork every three months for the first nine months of treatment, and those ...

Veozah is an oral, neurokinin 3 receptor antagonist indicated for the treatment of moderate to severe vasomotor symptoms due to menopause. The labeling for the product now includes a boxed warning ...

The U.S. Food and Drug Administration (FDA) has issued its most serious warning -- a black-box warning -- for Veozah, a medication used to relieve hot flashes in menopausal women, due to rare but ...

the FDA approved a new type of medication for the treatment of moderate to severe hot flashes called fezolinetant (brand name Veozah)," adds Nonacs. Minkin says that herbal remedies and ...

The FDA has issued a black-box warning for Veozah, a hot-flash medication, due to rare but serious liver risks Regular liver testing is recommended during Veozah treatment to ensure early ...